We were delighted to talk with Professor Jan Hedner (The University of Gothenburg, Gothenburg, Sweden) around the rationale, and safety and efficacy findings of using sulthiame in moderate to severe obstructive sleep apnoea.
The abstract ‘Safety and efficacy of sulthiame in moderate to severe obstructive sleep apnea: a randomized placebo-controlled parallel-group trial’ (Presentation ID 4383) was presented at ERS International Congress 2021, 5-8 September 2021.
Questions
- What have been the challenges of developing pharmacologic remedies for obstructive sleep apnoea (OSA)? (0:13)
- What is the mechanism of action of sulthiame and what is the rationale for its use in the treatment of OSA? (0:52)
- What were the aims, design and inclusion criteria of your study? (1:46)
- What were the primary and secondary outcome measures, and how well were they met? (2:22)
- What were the conclusions of the investigators, and what future studies are planned? (3:40)
- What are the hot topics and latest research you are looking forward to exploring in OSA during 2021? (4:20)
Disclosures: Jan Hedner is a share holder of IP related to the medication discussed.
Support:Â Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of ERS 2021 (Virtual).
